Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TOP1 | P11387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1131752 | 0.97 | CYP3A4 (0.55) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL30350108 | 0.97 | CYP3A4 (0.55) | CYP3A4TDP1ESR1ESR2DRD1 | |
| Bromide SCHEMBL8660152 | 0.97 | CYP3A4 (0.55) | CYP3A4TDP1ESR1ESR2DRD1 | |
| Water SCHEMBL1131329 | 0.97 | CYP3A4 (0.55) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL31059891 | 0.97 | CYP3A4 (0.55) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL28427105 | 0.89 | TDP1 (0.46) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL29635182 | 0.87 | TDP1 (0.50) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL4004840 | 0.87 | TDP1 (0.50) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL2322069 | 0.87 | ALDH1A1 (0.46) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL4000406 | 0.87 | CYP3A4 (0.44) | CYP3A4TDP1ESR1ESR2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 699 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086030-A1 | METHOD FOR CONSTRUCTING CHIRALITY OF PYRAN RING IN ORFORGLIPRON BY MEANS OF ENZYMATIC CATALYSIS | 成都安迈博生物医药有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20250333580-A1 | RESIN COMPOSITION AND PRODUCTS THEREOF | ELITE ELECTRONIC MAT ZHONGSHAN CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-4594306-A1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE PRODUCTION OF REMIBRUTINIB | Novartis AG (CH) | 2025-08-06 | — | — | EP | claimed |
| CN-120136818-A | Preparation method of optically active beta-butyrolactone | 万华化学集团股份有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-119798102-B | Preparation method and application of pure organic high-resolution glass scintillator | 厦门大学 | 2025-06-13 | — | — | CN | claimed |
| CN-119998265-A | Synthetic methods and intermediates for the production of rebaudinib | 诺华股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119798102-A | Preparation method and application of pure organic high-resolution glass scintillator | 厦门大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119462638-A | Preparation method of CDK 4/6 inhibitor | 上海皓元生物医药科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119371674-A | Preparation method of donor-acceptor type metal organic framework photocatalyst and application of photocatalytic amine oxide/thioether | 长沙理工大学 | 2025-01-28 | — | — | CN | claimed |
| CN-119372270-A | Method for constructing Orforglipron pyran ring chirality through enzyme catalysis | 成都安迈博生物医药有限公司 | 2025-01-28 | — | — | CN | claimed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-06-07 | — | — | US | claimed |
| EP-1792887-A1 | Process for the homogeneous hydrogenation of ketones using ruthenium catalytic systems | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-06-06 | — | — | EP | claimed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| EP-1757571-A1 | Process for the homogeneous hydrogenation of ketones using ruthenium catalytic systems. | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | claimed |
| EP-1716140-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES | Novartis AG (CH) | 2006-11-02 | — | — | EP | claimed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005075462-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | claimed |
| EP-1341798-A1 | CHIRAL DIPHOSPHINES AND THEIR METAL COMPLEXES | PPG-Sipsy (FR) | 2003-09-10 | — | — | EP | claimed |
| WO-2002040492-A1 | CHIRAL DIPHOSPHINES AND THEIR METAL COMPLEXES | PPG-SIPSY (FR) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | AGTR1, AGTR2, AGT | CYP3A4 769/4885TDP1 4366/4885ESR1 1356/4885 |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | GPR119, IGF1R, CCNE2 | CYP3A4 2700/4885TDP1 3610/4885ESR1 784/4885 |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, BRCA1 | CYP3A4 3236/4885TDP1 3636/4885ESR1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.